Drug Policy Watch · State Brief 2026

Colorado

Snapshot (structured)

Adult-use cannabis: Legal since 2012 (Amendment 64), retail sales since 2014
Medical cannabis: Legal since 2000 (Amendment 20)
Home grow: Yes, up to 6 plants per adult (3 flowering), 12 max per household, enclosed and locked
Intoxicating hemp / hemp THC: Tightly capped (1.75 mg THC per serving, 15:1 CBD:THC ratio under SB22-205); state weighing loosening hemp beverage limits ahead of the federal hemp ban
Psychedelics: Legal therapeutic access via the Natural Medicine program (Prop 122, 2022) plus personal-use decriminalization of psilocybin and other plant/fungi substances
Broad decriminalization: Partial; low-level possession reduced, plus Prop 122 personal-use psychedelics decriminalization
Harm reduction: Robust; legal syringe services, statewide naloxone access, legal fentanyl test strips, Good Samaritan law
Governor (party): Jared Polis (Democrat), term-limited, term ends January 2027
Legislature control: Democratic trifecta; Democrats hold both chambers
Citizen ballot initiatives allowed: Yes (statutory and constitutional initiatives)
Enclosure pressure score: 3/5

Cannabis

Colorado is the longest-running adult-use cannabis market in the United States. Voters legalized adult use through Amendment 64 in 2012, with licensed retail sales beginning in 2014. Adults 21 and older may possess up to 1 ounce of cannabis (or equivalent in infused products) and up to 8 grams of concentrate. Medical cannabis has been legal since voters passed Amendment 20 in 2000; registered patients may possess up to 2 ounces.

Home cultivation is permitted: each adult 21 and older may grow up to 6 plants (no more than 3 flowering at once), with a household cap of 12 plants regardless of how many adults live there. Plants must be kept in an enclosed, locked space that is not openly visible, which effectively prohibits outdoor grows visible to the public. No permit or medical card is required for recreational home grow. See Colorado MED home grow laws and MPP Colorado.

Market structure: Colorado allows but does not mandate vertical integration. The state issues several license types including cultivator, manufacturer, retailer, hospitality, hospitality-and-sales, business operator, testing facility, and transporter (cannabusinessplans.com). There are no statewide numeric caps on the number of licenses, though local jurisdictions may opt out or set their own limits. The mature market is consolidating: in 2025-2026, multistate operator Vireo Growth acquired 24 Colorado dispensaries and manufacturing assets from distressed MSO Schwazze (Medicine Man Technologies), expanding to roughly 41 Colorado stores, and Verdant Capital Partners agreed to acquire 17 of Native Roots' 21 Colorado dispensaries (MJBizDaily, MJBizDaily Vireo). Taxes are covered in the Market and barriers section.

Key 2026 actions: The legislature passed and Governor Polis signed SB26-007, allowing terminally ill registered medical patients to use non-smokable, non-inhalable cannabis products at health facilities that opt in; it takes effect August 12, 2026 (Marijuana Moment). A weed-friendly special-events bill (HB26-1117, bill number unconfirmed; reported as "HB 1117") died after its Senate sponsor pulled it late in session (Westword). SB26-161 to modernize cannabis-product regulation and move testing oversight was pending in committee at session's end.

Hemp

Colorado has among the strictest intoxicating-hemp rules in the country. SB22-205 and subsequent rulemaking cap finished hemp products at 1.75 mg of THC per serving and require a minimum 15:1 CBD-to-total-THC ratio in each serving and in the package (cannabisregulations.ai). ProPublica has documented that enforcement has nonetheless struggled to keep intoxicating hemp off shelves (ProPublica).

Federal exposure: A federal funding/appropriations measure signed in late 2025 narrowed the federal definition of hemp, shifting from a delta-9-only standard (0.3 percent by dry weight) to a total-THC standard that includes THCA, and capping finished consumable hemp products at 0.4 mg total THC per container. These changes take effect November 12, 2026, and would render most current THCA flower, high-potency vapes, concentrates, and delta-9 gummies federally non-compliant (Regulatory Oversight, Congress.gov CRS, The Haze Connect). Colorado's hemp sector is large and the changes are expected to be disruptive (KSUT, KSJD).

Recent state action: In response to the federal ban, Colorado advocates drafted an industry-backed effort to loosen state hemp-beverage caps, including allowing 5 to 10 mg THC hemp beverages where alcohol is sold (Colorado Politics, Axios Denver). That effort materialized as SB26-164 (Regulation of Lawful THC Beverages), but it was postponed indefinitely in the Senate Finance Committee on April 28, 2026, and did not pass (Gazette). Governor Polis, a longtime hemp advocate, publicly criticized the federal ban as disappointing.

Psychedelics

Colorado voters passed Proposition 122 (the Natural Medicine Health Act) in 2022, decriminalizing personal cultivation, use, and sharing of psilocybin, psilocin, DMT, ibogaine, and mescaline (not from peyote) for adults 21 and older, and establishing a regulated therapeutic-access program (Ballotpedia Prop 122). SB23-290 built out the regulatory framework.

Therapeutic access is now live. The Natural Medicine program licenses healing centers, cultivation, manufacturing, and testing facilities plus individual facilitators. The first healing center license was issued in early 2025, and by early 2026 Colorado had roughly 34 licensed healing centers with more applications pending (RMPBS, CPR). A key bottleneck has been the limited supply of licensed cultivation feeding regulated product to centers (Psychedelic Alpha).

2026 developments: Through June 1, 2026, regulated "natural medicine" was limited to psilocybin and psilocin. After June 1, 2026, on recommendation of the Natural Medicine Advisory Board, DORA may add DMT, ibogaine, and mescaline (excluding peyote) to the regulated definition (Vicente LLP, Manzuri Law). Specific standalone 2026 psychedelics bills are unconfirmed; check the live tracker below.

Broader drug policy

Decriminalization and sentencing: Colorado reduced penalties for low-level drug possession over the past decade, then partially reversed course on fentanyl with HB22-1326 (Fentanyl Accountability and Prevention), which increased some criminal penalties while also funding prevention, naloxone, and harm reduction (leg.colorado.gov HB22-1326). Cannabis-specific relief: 2020 Executive Order C2020-004 and 2021 Executive Order C2021-019 pardoned possession of up to 2 ounces; misdemeanor marijuana convictions for conduct now legal can be petitioned for sealing (Point Seven Group).

Harm reduction is comparatively strong. The state Department of Public Health and Environment (CDPHE) supports roughly 21 syringe access programs and a free fentanyl test strip distribution program across local public health agencies; fentanyl test strips are legal and liability protections were expanded under HB22-1326. Statewide naloxone standing orders make the overdose reversal drug broadly accessible, and Colorado has a Good Samaritan overdose immunity law (Network for Public Health Law 50-state survey, CDPHE naloxone standing orders). Note: some harm-reduction program counts date to 2023-2025 sources and may be stale.

Political landscape

Governor Jared Polis (Democrat) is term-limited, with his term ending January 12, 2027; 2026 is an open-seat gubernatorial election year (Ballotpedia Polis). Democrats hold a trifecta. Reported counts show Democrats controlling the Senate (about 23 of 35 seats) and the House (about 43 of 65 seats); the Senate President was reported as James Coleman (Colorado Democratic Party). Treat exact seat counts as approximate and verify against the General Assembly roster.

Key committees for drug policy include Senate Finance (where SB26-161 and SB26-164 were routed), Senate Business/Labor, and House Health and Human Services (which heard SB26-007). Named players: Sen. Kyle Mullica (D), a registered nurse, sponsored the medical-cannabis-in-facilities bill and the cannabis-product modernization bill; Sen. Julie Gonzales (D) led the THC beverage effort; Reps. Matthew Martinez (D) and Steven Woodrow (D) co-sponsored the beverage bill. Governor Polis is a longtime pro-hemp, pro-cannabis voice but criticized the opt-out amendment to SB26-007. Named consistent opponents in the legislature are unconfirmed; opposition to the THC beverage bill came in part from the licensed cannabis industry and via a stale fiscal note.

Ballot initiatives

Colorado allows citizen-initiated ballot measures, both statutory and constitutional, and has used them heavily for drug policy (Amendment 20 in 2000, Amendment 64 in 2012, Proposition 122 in 2022, Proposition 126 retail-delivery in 2022). No confirmed pending statewide 2026 cannabis, psychedelic, or drug-policy citizen initiative is identified in current sources; verify with the Colorado Secretary of State's initiative tracker. Treat the absence as unconfirmed rather than definitive.

Equity and expungement

Social equity: Colorado has a Social Equity Licensee program administered by the Marijuana Enforcement Division, with eligibility criteria amended effective April 1, 2025 (new applicant criteria available beginning February 1, 2025) (MED social equity eligibility). The state offers an accelerator program in which an accelerator-endorsed licensee can host and support a social equity licensee, with up to $50,000 in tax credits for at least 12 consecutive months of support. HB23-1020 and HB24-1061 addressed social equity licensing and industry support (HB23-1020, HB24-1061).

Expungement and record sealing: Because the Colorado Constitution constrains true expungement, past low-level cannabis crimes that are now legal are generally vacated and sealed rather than expunged. Individuals convicted of misdemeanor use or possession can petition for record sealing where the conduct would not be criminal if committed on or after December 10, 2012. Gubernatorial mass pardons (2020 and 2021 executive orders) covered possession of up to 2 ounces (Point Seven Group guide). Who is excluded: relief is largely petition-based for sealing (not fully automatic for all categories), and prior felony cultivation/distribution convictions are generally outside the pardon scope.

Market and barriers

Taxes: Retail (adult-use) cannabis carries a 15 percent state retail marijuana sales tax plus a 15 percent excise tax on the first wholesale transfer (based on Average Market Rate or actual price). The standard 2.9 percent state sales tax generally does not apply to retail marijuana that is subject to the 15 percent special sales tax, while medical marijuana is exempt from the 15 percent retail tax and pays the 2.9 percent state sales tax; local taxes add more (Denver effective rate reported near 27.9 percent all-in) (Colorado DOR marijuana excise tax, Colorado DOR sales tax, cannabispromotions.com Denver). The Department of Revenue resets Average Market Rates quarterly (most recently effective April 1, 2026) (DOR AMR April 2026).

Revenue: Marijuana sales generated over $236 million in state tax and fee revenue in 2025 (Colorado DOR press release), reflecting a maturing market with declining prices.

License caps, fees, residency: No statewide numeric license cap; local jurisdictions control local availability. Specific current application and annual license fee figures, capital requirements, and any residency requirement are best confirmed at the MED Licenses and Fees page; precise 2026 dollar amounts are unconfirmed here. Statewide licensee totals are published in the MED licensed facilities list; a single statewide count for 2026 was not confirmed in current sources (one local data point: about 62 retail and 84 medical stores in Colorado Springs).

Enclosure read

Colorado is an open, decentralized market by design (no license caps, home grow allowed, multiple license types, voter-driven expansion), which pulls the score down. But the market is mature and consolidating: distressed MSOs are being absorbed (Vireo buying Schwazze's Colorado retail, Verdant buying most of Native Roots), wholesale prices have fallen, and capital-intensive compliance plus the looming federal hemp squeeze favor larger operators. Social-equity provisions and home-grow rights keep a channel open for small players, but the trend line is toward fewer, larger owners of retail footprints. The hemp sector faces a sharp federal enclosure on November 12, 2026, that could push intoxicating-hemp commerce into the regulated cannabis system controlled by licensed operators. Net: moderate enclosure pressure, scored 3/5, with downward pressure from openness and upward pressure from M&A consolidation and federal hemp tightening.

What to watch next

November 12, 2026: Federal hemp definition change takes effect; expect major disruption to Colorado intoxicating-hemp products and possible state response.
August 12, 2026: SB26-007 (medical cannabis in opt-in health facilities) takes effect.
After June 1, 2026: DORA may expand regulated "natural medicine" to add DMT, ibogaine, and mescaline on Advisory Board recommendation.
Quarterly: Department of Revenue resets cannabis Average Market Rates (next reset after the April 1, 2026 rate).
2026 election: Open-seat governor race (Polis term-limited); the next governor will shape drug policy from January 2027.
Next legislature: The 76th General Assembly, First Regular Session, convenes January 11, 2027; expect renewed hemp-beverage and cannabis-product legislation after SB26-164 and SB26-161 stalled.
Watch the Secretary of State initiative filings for any 2026 ballot measures.

Regulators

Marijuana Enforcement Division (MED), within the Colorado Department of Revenue: licenses and regulates medical and adult-use cannabis (med.colorado.gov).
Colorado Department of Revenue (DOR), Taxation Division: cannabis taxes and Average Market Rates (tax.colorado.gov).
Colorado Department of Public Health and Environment (CDPHE): hemp/food safety, harm reduction (syringe services, fentanyl test strips, naloxone), and the medical marijuana registry; would gain cannabis testing oversight if SB26-161 advances.
Department of Regulatory Agencies (DORA), Natural Medicine Division: licenses and regulates psilocybin healing centers, facilitators, and the Natural Medicine program (dnm.colorado.gov).
Colorado Department of Agriculture: industrial hemp cultivation registration.

Federal exposure (2026)

Colorado sits at the leading edge of nearly every state-federal fault line in 2026, and as the oldest adult-use market with a live psilocybin program it is unusually exposed across multiple federal levers at once.

Rescheduling and 280E. Cannabis remains Schedule I by default federally. A DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III, leaving recreational cannabis on Schedule I. The practical effect in Colorado: the state's registered medical-marijuana operators and the patient-facing medical channel gain relief from IRS Section 280E, which had barred ordinary business deductions, while the much larger adult-use side, the bulk of Colorado's roughly $236 million annual tax-and-fee base, sees no 280E relief and no change to its federal status. Schedule III does not legalize cannabis, does not authorize interstate commerce, and does not cover state recreational businesses, so Colorado's adult-use supply chain stays federally illicit and intrastate. A broader DEA rescheduling hearing opened June 29, 2026, and may slip to 2027; any wider move is not yet law and should be tracked, not assumed.

The November 12, 2026 hemp cliff. FY2026 agriculture appropriations (Sec. 781, sponsored by Rep. Andy Harris, R-MD) narrowed the federal hemp definition to a total-THC standard of roughly 0.4 mg THC per container, recriminalizing an estimated 90 to 95 percent of intoxicating hemp products effective November 12, 2026. A delay bill, H.R.7010, was not enacted, and the 2026 Farm Bill (H.R.7567) keeps the ban. For Colorado the practical effect is narrower than in permissive states, because Colorado already imposes among the strictest intoxicating-hemp caps in the country (1.75 mg THC per serving, 15:1 CBD-to-THC ratio under SB22-205). Colorado's products were already far more constrained than the federal floor, so the cliff is less of a shock to compliant in-state product than it is elsewhere, but the federal total-THC accounting (including THCA) still sweeps in THCA flower, high-potency vapes, and concentrates that have leaked onto Colorado shelves despite state rules, and it forecloses the looser hemp-beverage market Colorado advocates had hoped to open. SB26-164, the bill to permit 5 to 10 mg THC hemp beverages in grocery and retail settings, was postponed indefinitely on April 28, 2026, so Colorado entered the federal deadline without a state expansion to cushion or redirect displaced hemp demand. The likely channel is consolidation of intoxicating-hemp commerce into the licensed cannabis system controlled by existing operators.

Banking. SAFER Banking has stalled in Congress, so Colorado cannabis businesses, recreational and medical alike, remain largely cut off from mainstream banking, card payments, and conventional lending. This is the financial engine behind the consolidation already visible in the state: capital-constrained, cash-heavy, federally unbankable operators are easier targets for distressed-asset acquisition, which is exactly the dynamic seen in Vireo Growth absorbing Schwazze's Colorado retail and Verdant acquiring most of Native Roots. Continued banking failure compounds 280E exposure on the adult-use side and tilts the playing field toward well-capitalized multistate operators (MSOs).

Psychedelics. This is Colorado's most distinctive federal tension. Psilocybin, psilocin, MDMA, ibogaine, and mescaline remain Schedule I federally, yet Colorado runs a live, voter-mandated Natural Medicine program with roughly 34 licensed healing centers offering supervised psilocybin access. An April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA commissioner priority vouchers (reportedly to Compass Pathways and Usona for psilocybin and to Otsuka for an MDMA relative) are fast-tracking FDA review, but there is no FDA approval yet, and federal rescheduling is conditional on approval. Critically, an FDA approval would create a pharmaceutical, prescription pathway for a standardized psilocybin product; it would not, by itself, legitimize or alter Colorado's facilitator-led, healing-center supervised-access model, which uses whole-fungi natural medicine outside the FDA drug framework. Colorado has already legislated for this split: Governor Polis signed SB26-031 on April 20, 2026, which automatically exempts from state Schedule I any prescription product containing a Schedule I substance once the FDA approves it and the DEA reschedules it, while explicitly carving out natural medicine and marijuana so that Proposition 122's program remains intact (leg.colorado.gov SB26-031, Westword). The result is a likely two-track future: a federally sanctioned pharmaceutical psilocybin product flowing through pharmacies and prescribers, alongside Colorado's state-only supervised-access program that stays federally Schedule I and therefore federally illegal regardless of any FDA action. Commentators have warned Colorado to "keep faith" with the natural-medicine model rather than let the pharmaceutical track crowd it out (Colorado Newsline).

Harm reduction. SAMHSA guidance issued April 24, 2026 bars federal funds from being used for fentanyl (and xylazine and medetomidine) test strips, clean syringes, and sterile water, while naloxone remains supported. Colorado has comparatively robust harm reduction: roughly 21 syringe access programs, a free fentanyl test strip distribution program, statewide naloxone standing orders, and a Good Samaritan law, with state-law protections for test strips under HB22-1326. The federal exposure is funding, not legality: Colorado's syringe services and test strip distribution stay legal under state law, but programs that draw on federal streams such as the State Opioid Response (SOR) grant can no longer buy strips, syringes, or sterile water with those dollars. The practical effect is budgetary pressure that pushes the cost of test strips and syringe supplies onto state and local funds, philanthropy, or the programs themselves, even as naloxone access is preserved (NACo, STAT). Fentanyl itself is permanently Schedule I after the HALT Fentanyl Act (July 17, 2025), reinforcing the enforcement posture behind the SAMHSA cuts.

Patient access and rights

This section covers what Colorado law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): Colorado enacted a Ryan's Law protection in 2026. Senate Bill 26-007 requires health care facilities to allow a qualifying patient to use medical cannabis on site, but with a limit patients should know: a facility may opt out. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), with Pennsylvania's bill pending.

Broader protections: outside that new law, Colorado is weak. A review of Colorado law found no statutory protection for a medical cannabis patient in any of the six areas other states cover: not employment (the Colorado Supreme Court held in Coats v. Dish Network that off-duty medical use is not protected), not housing, not a custody or visitation dispute, not placement on an organ transplant list, not school enrollment, and no general medical-care protection. Apart from hospital access, a Colorado patient has no enforceable shield in these situations.

Out-of-state patients: Colorado does not offer medical reciprocity; adults 21 and over use the adult-use market, which rests on a different legal footing from a medical patient's protections.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine, and it creates no hospital-use right or employment, housing, custody, transplant, or school protection; the protections and limits above are creatures of Colorado law, not federal law.

Sources: Colorado's Ryan's Law, Senate Bill 26-007; the general medical-use provision, Colorado Revised Statutes Section 25-1.5-106.

Analysis: the enclosure read in depth

Colorado is the country's oldest adult-use cannabis market, and its design choices, no statewide license caps, legal home grow of up to six plants per adult, multiple unbundled license types, and repeated voter-driven expansion, are genuinely anti-enclosure features. They keep entry channels open and prevent the kind of hard numeric license scarcity that drives rent extraction in cap-and-license states. That openness is the main reason the state does not score higher than a 3 out of 5. But maturity cuts the other way. A market this old is consolidating, and the federal layer accelerates that consolidation rather than checking it. The combination of no 280E relief for adult-use operators, no banking access under a stalled SAFER Banking, and falling wholesale prices makes small and mid-size Colorado operators chronically capital-starved and federally unbankable, which is precisely the condition under which distressed assets get rolled up. The Vireo absorption of Schwazze's Colorado retail and Verdant's acquisition of most of Native Roots are not anomalies; they are the predictable output of a system where federal policy denies ordinary financial oxygen to everyone except those with outside capital, which favors larger MSOs.

Hemp is where the enclosure logic is sharpest. Colorado's strict intoxicating-hemp caps already fenced out most high-THC hemp product at the state level, and the November 12, 2026 federal cliff recriminalizes roughly 90 to 95 percent of intoxicating hemp nationally on a total-THC basis. The informal and small-scale hemp economy, smoke shops, THCA flower sellers, independent beverage makers, has the least capital and the least ability to absorb a compliance shock, so it is the most thoroughly fenced out. With SB26-164 dead, the demand those products served does not get a new legal home in a loosened state beverage market; the most likely destination is the licensed, capital-intensive cannabis channel that incumbents already control. That is enclosure in its clearest form: a federal standard plus a failed state liberalization route funneling a formerly open, informal market into a regulated system owned by larger players.

The state-plus-federal interaction is most interesting and most uncertain in psychedelics. Here Colorado has actively built a commons counter-move. Proposition 122 created a voter-mandated, facilitator-led supervised-access model that does not depend on FDA approval or pharmaceutical sponsorship, and SB26-031 deliberately walls that model off from the incoming federal pharmaceutical track by carving out natural medicine while still letting FDA-approved psilocybin medicines in automatically. The federal medicalize-and-control posture, an executive order plus FDA priority vouchers steering psychedelics toward standardized, patentable, prescription products from a handful of sponsors, is a textbook enclosure vector: it would hand the legitimate, reimbursable, federally lawful version of psilocybin to large pharmaceutical incumbents while Colorado's broader, lower-cost, non-pharmaceutical access stays Schedule I and federally illegal. The open question is whether the two tracks coexist or whether payers, clinicians, and capital migrate to the FDA product and starve the state program. Colorado's structural choice to keep the natural-medicine commons explicitly separate is the strongest anti-enclosure move in the brief, but its durability depends on funding, facilitator supply (already a bottleneck), and political will after Polis leaves office in January 2027.

What to watch: the June 29, 2026 DEA rescheduling hearing (and whether it slips to 2027) for any widening of cannabis relief beyond the medical category; the November 12, 2026 hemp cliff and any special-session or 2027 state response; the first FDA psilocybin approval, which would trigger SB26-031's automatic pharmaceutical pathway and test whether Colorado's supervised-access commons can hold its ground; the fate of SAFER Banking, the single biggest variable in whether consolidation continues; and the 2026 open-seat governor race, since the next administration will set the tone on hemp, psychedelics, and harm-reduction funding backfill. Commons counter-moves are real here, home grow, the social-equity and accelerator licensing programs, the voter-built natural-medicine model, and SB26-031's explicit carve-out, but they sit inside a federal environment whose enclosure read consistently favors large incumbents and fences out small, informal, and hemp actors. On balance, openness by design pulls down and federal-plus-consolidation pressure pulls up, leaving the score at a moderate 3 out of 5.

Active legislation (2026)

The 2026 regular session ran January 14 to May 13, 2026, so these bills are from the just-concluded session. This list is not exhaustive; for the long tail and live status use LegiScan Colorado, the Colorado General Assembly bill search.

Beyond the live tracker

These measures are not in the live bill list below: some are not bills (executive orders, rules, referendums, or budgets), and some are proposals or prior-session measures the live tracker does not currently carry.

SB26-007 Medical Marijuana Use in Health Facilities (Signed by Governor Mar 30, 2026; effective Aug 12, 2026)
SB26-161 Modernize Regulation of Cannabis-Related Products (moves testing oversight from DOR/MED to CDPHE) (Introduced, assigned to Finance; did not advance to enactment (status as of session end))
SB26-164 Regulation of Lawful THC Beverages (hemp-derived THC drinks) (Postponed indefinitely in Senate Finance Apr 28, 2026 (failed))
HB26-1117 (number unconfirmed; reported as "HB 1117") Cannabis special-event permits (Died; Senate sponsor pulled the bill late in session)

Bill	Title/Topic	Chamber	Status	Sponsor(s)
SB26-007	Medical Marijuana Use in Health Facilities	Senate (origin)	Signed by Governor Mar 30, 2026; effective Aug 12, 2026	Sen. Kyle Mullica (D)
SB26-161	Modernize Regulation of Cannabis-Related Products (moves testing oversight from DOR/MED to CDPHE)	Senate	Introduced, assigned to Finance; did not advance to enactment (status as of session end)	Sen. Kyle Mullica (D), Rep. Marc Snyder (D)
SB26-164	Regulation of Lawful THC Beverages (hemp-derived THC drinks)	Senate	Postponed indefinitely in Senate Finance Apr 28, 2026 (failed)	Sen. Julie Gonzales (D), Reps. Matthew Martinez (D) and Steven Woodrow (D)
HB26-1117 (number unconfirmed; reported as "HB 1117")	Cannabis special-event permits	House	Died; Senate sponsor pulled the bill late in session	Sponsor unconfirmed

Notes: A reported wholesale-tax change for cannabis was among bills discussed early in session; specifics and final disposition unconfirmed (Westword overview). No standalone 2026 psychedelics statute is confirmed here.

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →